ETFs & Funds
Home›ETFs & Funds›ETFs›ALPS Medical Breakthroughs ETF SBIO falls amid higher…
ALPS Medical Breakthroughs ETF SBIO falls amid higher rate concerns
Despite a recent correction tied to rising Treasury yields and the Fed’s rate hike, SBIO is still up about 14% year to date, and its underlying holdings are structured to hold cash for at least two years at current burn rates.
ETF Trends reports the ALPS Medical Breakthroughs ETF (SBIO) is in a correction, with rising Treasury yields and the Federal Reserve’s recent interest rate hike cited as likely drivers.
Despite the pullback, SBIO remains up about 14% year to date, and ETF Trends notes a case for investors potentially overreacting to the impact of higher rates on biotech stocks.
The article also points to biotech financing needs, while adding a structural detail for SBIO’s components: they are required to hold enough cash to survive at least two years at current burn rates.
ETF Trends further highlights why investors may still look at SBIO, pointing to big pharma’s push to access innovation through licensing deals and deal-making to rebuild pipelines as some blockbuster drugs face patent expirations, citing Barron’s for related context.